Fat-to-heart crosstalk in health and disease

Front Genet. 2023 Mar 24:14:990155. doi: 10.3389/fgene.2023.990155. eCollection 2023.

Abstract

According to the latest World Health Organization statistics, cardiovascular disease (CVD) is one of the leading causes of death globally. Due to the rise in the prevalence of major risk factors, such as diabetes mellitus and obesity, the burden of CVD is expected to worsen in the decades to come. Whilst obesity is a major and consistent risk factor for CVD, the underlying pathological molecular communication between peripheral fat depots and the heart remains poorly understood. Adipose tissue (AT) is a major endocrine organ in the human body, with composite cells producing and secreting hormones, cytokines, and non-coding RNAs into the circulation to alter the phenotype of multiple organs, including the heart. Epicardial AT (EAT) is an AT deposit that is in direct contact with the myocardium and can therefore influence cardiac function through both mechanical and molecular means. Moreover, resident and recruited immune cells comprise an important adipose cell type, which can create a pro-inflammatory environment in the context of obesity, potentially contributing to systemic inflammation and cardiomyopathies. New mechanisms of fat-to-heart crosstalk, including those governed by non-coding RNAs and extracellular vesicles, are being investigated to deepen the understanding of this highly common risk factor. In this review, molecular crosstalk between AT and the heart will be discussed, with a focus on endocrine and paracrine signaling, immune cells, inflammatory cytokines, and inter-organ communication through non-coding RNAs.

Keywords: adipose tissue; cardiovascular disease; crosstalk; heart failure; inflammation; microRNAs.

Publication types

  • Review

Grants and funding

TM received funding from the National Institute of Health by grants HL116848, HL147558, DK119594, HL127240, and HL150225, and a grant from the American Heart Association (16SFRN31400013). ER is supported by an American Heart Association Postdoctoral fellowship (#829504) and a Colorado Clinical and Translational Sciences Institute (CCTSI) Pilot Grant award (#CO‐J‐22‐9).